Point of care CYP2C19 genotyping after percutaneous coronary intervention

[1]  Yee Ming Lee,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update , 2022, Clinical pharmacology and therapeutics.

[2]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[3]  M. Whirl‐Carrillo,et al.  PharmVar GeneFocus: CYP2C19 , 2020, Clinical pharmacology and therapeutics.

[4]  L. Been,et al.  Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes , 2020, JACC. Basic to translational science.

[5]  N. Limdi,et al.  Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples , 2019, Clinical and translational science.

[6]  Neil A. Miller,et al.  PharmVar and the Landscape of Pharmacogenetic Resources , 2019, Clinical pharmacology and therapeutics.

[7]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[8]  S. Scott,et al.  Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[9]  J. Shaw,et al.  Practical challenges related to point of care testing , 2015, Practical laboratory medicine.

[10]  H. Gurm,et al.  Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). , 2015, The American journal of cardiology.

[11]  W. Cantor,et al.  Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. , 2014, The Canadian journal of cardiology.

[12]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[13]  Michael V Holmes,et al.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. , 2011, JAMA.

[14]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[15]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[16]  R. Weinshilboum,et al.  The Impact of Pharmacogenomics on the Management of Cardiac Disease , 2011, Clinical pharmacology and therapy.

[17]  S. Scott,et al.  CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients , 2011, Circulation. Cardiovascular interventions.

[18]  S. Kaul,et al.  ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association , 2010, Circulation.

[19]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[20]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.